HBIO Harvard Bioscience Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HBIO

Price (delayed)

$6

Market cap

$27.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.17

Enterprise value

$62.53M

?
Relative Growth: Rel. Growth: 32
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: 43
Relative Profitability: Rel. Profitability: 41

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned ...

Highlights
The company's net income has surged by 83% YoY and by 83% QoQ
The EPS has soared by 83% YoY and by 83% from the previous quarter
HBIO's quick ratio has soared by 168% YoY but it is down by 19% QoQ
The equity has declined by 32% year-on-year and by 27% since the previous quarter
Harvard Bioscience's revenue has decreased by 6% YoY
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.harvardbioscience.com
Peers: BRKR A TMO JNJ

Key stats

What are the main financial stats of HBIO

HBIO stock price

How has the Harvard Bioscience stock price performed over time
Intraday
-3.07%
1 week
-3.69%
1 month
-1.32%
1 year
5.26%
YTD
-10.31%
QTD
-2.44%

Financial performance

How have Harvard Bioscience's revenue and profit performed over time
Revenue
$85.53M
Gross profit
$49.97M
Operating income
-$86,000
Net income
-$9.78M
Gross margin
58.4%
Net margin
-11.4%
HBIO's operating income has surged by 100% year-on-year and by 100% since the previous quarter
Harvard Bioscience's operating margin has soared by 100% YoY and by 100% from the previous quarter
Harvard Bioscience's net margin has soared by 83% from the previous quarter and by 82% YoY
The company's net income has surged by 83% YoY and by 83% QoQ

Price vs fundamentals

How does HBIO's price correlate with its fundamentals

Growth

What is Harvard Bioscience's growth rate over time

Valuation

What is Harvard Bioscience stock price valuation
P/E
N/A
P/B
2.67
P/S
0.31
EV/EBIT
N/A
EV/EBITDA
39.48
EV/Sales
0.73
The EPS has soared by 83% YoY and by 83% from the previous quarter
HBIO's price to book (P/B) is 57% more than its last 4 quarters average of 1.7 and 16% more than its 5-year quarterly average of 2.3
The equity has declined by 32% year-on-year and by 27% since the previous quarter
The stock's price to sales (P/S) is 74% less than its 5-year quarterly average of 1.2 but 3.3% more than its last 4 quarters average of 0.3
Harvard Bioscience's revenue has decreased by 6% YoY

Efficiency

How efficient is Harvard Bioscience business performance
HBIO's return on invested capital has surged by 93% since the previous quarter and by 92% year-on-year
The ROS has soared by 92% from the previous quarter and by 92% YoY
The return on assets has surged by 83% since the previous quarter and by 75% year-on-year
The return on equity has surged by 81% since the previous quarter and by 34% year-on-year

Dividends

What is HBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HBIO.

Financial health

How did Harvard Bioscience financials performed over time
The total assets is 15% more than the total liabilities
HBIO's quick ratio has soared by 168% YoY but it is down by 19% QoQ
HBIO's current ratio has surged by 146% year-on-year but it is down by 10% since the previous quarter
The company's debt to equity rose by 46% YoY and by 36% QoQ
The equity has declined by 32% year-on-year and by 27% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.